Mcl-1 Cancer Research Results

Mcl-1, myeloid cell leukemia 1: Click to Expand ⟱
Source: HalifaxProj(inhibit)
Type:
A member of the Bcl-2 family of proteins, which play a crucial role in regulating apoptosis, or programmed cell death. In cancer, Mcl-1 is often overexpressed, contributing to the development and progression of various types of tumors.
Mcl-1 is often overexpressed in several cancers, including hematological malignancies (like leukemia and lymphoma) and solid tumors (such as breast, lung, and prostate cancers).
Mcl-1 inhibits apoptosis by binding to pro-apoptotic proteins, preventing them from triggering the cell death pathway.


Nor, Normal Healthy: Click to Expand ⟱
Normal Healthy
Scientific Papers found: Click to Expand⟱
7159- CHA,    ROS-mediated inactivation of the PI3K/AKT pathway is involved in the antigastric cancer effects of thioredoxin reductase-1 inhibitor chaetocin
- vitro+vivo, GC, HGC27 - in-vitro, GC, AGS - in-vitro, GC, BGC-823 - in-vitro, GC, SGC-7901 - in-vitro, Nor, HEK293
TumCP↓, TumCCA↑, Casp↑, Apoptosis↑, TrxR1↓, ROS↑, eff↓, eff↑, PI3K↓, Akt↓, TumCG↓, cl‑PARP↑, cl‑Casp3↑, cl‑Casp9↑, cl‑Casp8↑, Bcl-2↓, Bcl-xL↓, Mcl-1↓, XIAP↓, survivin↓, TumVol↓, TumW↓, Weight∅, toxicity↓, Ki-67↓, other↝,
6814- EMD,    Emodin: A Review of its Pharmacology, Toxicity and Pharmacokinetics
- Review, Nor, NA
AntiCan↑, *hepatoP↑, *Inflam↑, *antiOx↑, *AntiBio↑, *BioAv↓, *AntiViral↑, *AntiDiabetic↑, *neuroP↑, CSCs↓, NOTCH↓, β-catenin/ZEB1↓, STAT3↓, TumCCA↑, *TNF-α↓, IL6↓, IL1β↓, *MMP9↓, *HO-1↑, cMyc↓, Mcl-1↓,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

ROS↑, 1,   TrxR1↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

XIAP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

cMyc↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 1,   Apoptosis↑, 1,   Bcl-2↓, 1,   Bcl-xL↓, 1,   Casp↑, 1,   cl‑Casp3↑, 1,   cl‑Casp8↑, 1,   cl‑Casp9↑, 1,   Mcl-1↓, 2,   survivin↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 1,  

DNA Damage & Repair(tgid=10) ⓘ

cl‑PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

TumCCA↑, 2,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CSCs↓, 1,   NOTCH↓, 1,   PI3K↓, 1,   STAT3↓, 1,   TumCG↓, 1,  

Migration(tgid=13) ⓘ

Ki-67↓, 1,   TumCP↓, 1,   β-catenin/ZEB1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL1β↓, 1,   IL6↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

eff↓, 1,   eff↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

IL6↓, 1,   Ki-67↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   toxicity↓, 1,   TumVol↓, 1,   TumW↓, 1,   Weight∅, 1,  
Total Targets: 36

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

AntiBio↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   HO-1↑, 1,  

Migration(tgid=13) ⓘ

MMP9↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Inflam↑, 1,   TNF-α↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiDiabetic↑, 1,   hepatoP↑, 1,   neuroP↑, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiViral↑, 1,  
Total Targets: 11

Scientific Paper Hit Count for: Mcl-1, myeloid cell leukemia 1
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:49  Cells:%  prod#:%  Target#:182  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page